Cutaneous Melanoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Melanoma (966)

Ocular Melanoma (108)

Uveal Melanoma (104)

Mucosal Melanoma (32)

Melanoma (966)

Ocular Melanoma (108)

Uveal Melanoma (104)

Mucosal Melanoma (32)

›

No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	TC Sensitive: A2 - Guideline TC Sensitive : A2	TC Sensitive: A2 - Guideline TC Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	trametinib Resistant: A2 - Guideline trametinib Resistant : A2	trametinib Resistant: A2 - Guideline trametinib Resistant : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	dabrafenib + SNR1611 Sensitive: A2 - Guideline dabrafenib + SNR1611 Sensitive : A2	dabrafenib + SNR1611 Sensitive: A2 - Guideline dabrafenib + SNR1611 Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	pembrolizumab + dabrafenib Sensitive: A2 - Guideline pembrolizumab + dabrafenib Sensitive : A2	pembrolizumab + dabrafenib Sensitive: A2 - Guideline pembrolizumab + dabrafenib Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	CVD Sensitive: A2 - Guideline CVD Sensitive : A2	CVD Sensitive: A2 - Guideline CVD Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2	encorafenib + binimetinib Sensitive: A2 - Guideline encorafenib + binimetinib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : C1	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : C1
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : A2

Cutaneous Melanoma

Associations(87)

Associations
(87)